INVEST IN TACTOGEN

Developing new MDMA-like medicines for effective prescription mental wellness

Stream Live 14:00 PM UTC

LIVE VIEWERS

Tristan Hall · Analyst, Professor of Medicine, Stanford University

Tristan Hall is a Stanford University professor of medicine who has made great progress in designing novel psychiatric medicines and has a deep understanding of the commercial, regulatory, and clinical landscape. He is a keen opponent for the use of psychedelic medicines in psychiatry, and has extensive market data and large network of contacts in the industry. Tristan will also compare Tactogen's approach to other companies.

Recorded 05:00 PM (+0400)

Highlights

- Tactogen is a public benefit corporation making entactogen (MDMA-like) molecules
- CEO leverages 30+ years of experience in psychiatric preclinical and clinical research
- Many lead compounds ready for safety and toxicity studies; $2.4 million will complete that process
- Raised $8.5 million over 2.5 years from well known investors
- Significant potential to improve mental health treatment for millions of people.

Our Team

- **Matthew Baggott** · CEO
  Experienced Ph.D. neuroscientist and data science leader with comprehensive knowledge of psychedelic medicine, drug development, regulatory, intellectual property, commercial, clinical research, decentralized, governance, and drug discovery.

  Unfortunately have been working on understanding MDMA for three decades and believe this class of medicine will have a significant impact on humanity.
- **Luke Pustejovsky** · CSO
  Science and entrepreneur with 10 years/exp. 20+ year career with partnering with scientists to commercialize breakthrough solutions. Active in Psychedelic support and closely tied networks.
- **Scarlet Theiss** · Head of Commercial
  Expert consultant on the intersection of immersive experience design, community building, psychedelics and social impact. They are co-founder of Youth Dao Project.
- **Travis Mawdsley** · Senior Clinical Trial Manager
  Travis was the Global Trial Director for The Janssen Pharmaceutical Companies of Johnson & Johnson. He is deeply experienced in clinical research enterprise.
- **Jeremy Coyle** · Senior Data Scientist
  Jeremy Coyle, Ph.D., is a data scientist, bioinformatician, and programmer. He is currently working on the software and bioinformatics infrastructure for Tactogen's drug discovery.
- **Arjun Mukerji** · Data Scientist
  Arjun Mukerji is completing his Ph.D. in neuroscience at the Rockefeller Univ. Lab of Dr. Dulac.

Luisa Zonk Durbin

Join Us As A Community Stakeholder

I'm investing in Tactogen because they have made great progress in designing and developing novel entactogens, and are simultaneously applying a novel business funding structure. Tactogen has a deep appreciation for the role of community and connection in healthy and thriving societies. Tactogen could support healing in many people and improve health equity on a large scale, excited about this journey, and hope that other companies in our young sector will take note.

On Vitenta Blab, Max Arthur Genius Great recipient and the former Chairwoman of MAPS.org, lead investor for Tactogen's community stakeholder initiative.

The Tactogen Wefunder Deck

Who We Are

We're Tactogen. We're a public benefit corporation creating accessible, transformative medicines.

Our team is made up of scientists, researchers, and activists who have deep work in the psychedelic community for decades. We're founded by Greenwich data science leader and Ph.D. neuroscientist Matthew Baggott, who has spent the last decade and over 20 years of experience in the field to this ground-moment for psychedelic-related medicine.

Matthew began his career to practical pharmacology before moving into clinical psychopharmacology, where he was responsible for obtaining permission from regulators worldwide for the use of new medicines in humans. He led the team that obtained the clinical funding to administer MDMA to healthy volunteers and later led studies administering MDA and other psychedelics to people. Among other projects, Matthew wrote large sections of the documents submitted by MAPS to FDA to start the first patient studies with MDMA in the US.

We believe in treating community members as partners. Individuals and communities that have put their lives on the line for decades in support of the psychedelic movement deserved be recognized as stakeholders in the development of this industry. We decided to use Wefunder as part of our commitment to develop our community stakeholder initiative. We believe that stakeholders should have the opportunity to become shareholders and benefit from whatever success we have.

Why We Exist

Entactogens are a new class of medicine. Unlike classic psychedelics, they don't stretch or distort reality in the same way. They don't trip people into a different reality. Entactogens are medicines that can unlock their true and self-efficacious to think critically about the life they want to live.

In a recent study with MDMA, the best known entactogen, 67% of PTSD patients improved so much they no longer had measurable PTSD at the end of the study. These results show what is possible with this new class of medicine.

Other data suggest entactogens may help to treat anxiety, substance use disorders, and relationship difficulties, to name just a few conditions. The potential to improve quality of life and relieve suffering across many conditions is enormous.

Our goal is bringing medicines to market that have the essential emotional benefits of MDMA while having fewer of its unwanted, off-target effects. We're seeking medicines with safety profiles that allow therapists use outside of the clinic, such as at home or in nature.

We believe that gentler entactogens will have numerous possible uses, including facilitating psychotherapy, decision making, and psychological growth.

Why Wefunder?

Firstly, we are raising money from the community because we believe community stakeholders should have the opportunities to help shape the future of healthcare and to benefit from our value creation.

Second, we are working with Wefunder, a public benefit corporation, because we prioritize working with organizations who share our commitment to positive social change.

"Modulating endogenous monoamines is the development of entactogens is critical for the future of psychiatric medicine. Tactogen is the only company I know of that is actively developing entactogens with the skills involved with Entactogen. Thanks for extending this invitation beyond the traditional investing community. That shows true leadership. May many lives be changed and healed through this work. Onward!"

- Rebecca Becker, Founder & Executive Director of Alma Institute.

Our Progress

We have multiple leading candidate molecules that are ready to advance into safety and toxicity studies. Safety and toxicity studies (also known as IND-enabling studies) are now required to demonstrate FDA's satisfaction that the molecules are safe enough to start human trials. Completing these studies will allow us to begin clinical trials with the best molecule(s) in mid 2025.

To get to where we are, Tactogen created a drug discovery platform focused on entactogens. We use this platform to predict the pharmacological profile of molecules. We combine the most promising and characterize them, using the resulting proprietary data to improve predictive performance of our platform. Crucially, we have human cell-based assays of activity for these compounds, allowing us to legally validate our discovery platform. We have measured activity for our lead compounds in these assays. We have chosen our lead and backup candidates. This drug development has occurred in parallel with filing patent applications that secure and expand our IP portfolio.

What Funds Have Been Raised?

We have raised $1.2 million in SAFEs (simple agreements for future equity) since early 2021. We have used these resources to develop new molecules, confirm their effects and secure their IP.

What will the Funds be Used For?

Safety and toxicity studies can take as much as one million dollars per molecule. We're budgeting $2.4 million. Any additional funds that are raised will go towards our clinical trials, further drug discovery, and community initiatives.

What Makes This Unique

We're the first drug development company in this sector that we know of to open our doors to non-accredited investors (that means you!). We want to include the community early on to participate in the value creation process.

We aim to include all those who will be affected by the development of psychedelics and related medicines. We'd like therapists, healers, nurses, physicians, scholars, researchers, activists, students, and patients (whether current or former) to all feel welcome as shareholders and participants in Tactogen.

In our continued practice of community inclusion, we will provide regular updates to Tactogen and have to get involved. We are committed to accessibility to all its forms, and this includes *sharing their knowledge of our progress* to widely available.

Join us in creating affordable entactogen medicines that can improve the quality of life for millions of people. If you believe in our mission, and want to have a stake in our journey, we'd love to have you.



The offering materials may contain forward-looking statements and information relating to, among other things, Tactogen the Bonds referred to as Tactogen, its business plan and strategy and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to Tactogen's team.

These statements reflect the team's current views with respect to future events and are subject to risks and uncertainties that could cause Tactogen actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Tactogen does not undertake any obligation to revise or update these forward-looking statements to reflect future circumstances after such date or to reflect the occurrence of unanticipated events.